EPISODE · Mar 13, 2026 · 33 MIN
Drug Fix: US FDA’s Prasad Leaves, Harry Potter, And Is CNPV Effective Because Of RTOR?
from Citeline Podcasts · host Norstella
Pink Sheet Executive Editor Derrick Gingery, Managing Editor Bridget Silverman and Editor-in-Chief Nielsen Hobbs discuss potential directions for the US Food and Drug Administration’s Center for Biologics Evaluation and Research after the departure of Director Vinay Prasad (:32), including similarities between the center’s leadership issues and the staffing problems in the Harry Potter saga’s Hogwarts School of Witchcraft and Wizardry (7:48), as well as the potential policy implications (10:11). They also discuss the contributions of the agency’s Real-Time Oncology Review (RTOR) pilot program to the quick reviews of two Commissioner’s National Priority Voucher (CNPV) awardees (17:19). More On These Topics From The Pink Sheet US FDA’s Vinay Prasad, Controversial CBER Director, Leaving In April: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/us-fdas-vinay-prasad-controversial-cber-director-leaving-in-april-DJO7ACE73RCNTLZKQWCN2S26LM/ US FDA’s CNPV Approvals Ride RTOR Pilot’s Coattails: https://insights.citeline.com/pink-sheet/pathways-and-standards/review-pathways/us-fdas-cnpv-approvals-ride-rtor-pilots-coattails-3HEGU5MDWJEG7OYHSZQR6TE5NM/
Embed this episode
NOW PLAYING
Drug Fix: US FDA’s Prasad Leaves, Harry Potter, And Is CNPV Effective Because Of RTOR?
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.